NYSE: HIMS · Medical Care Facilities
Hims & Hers Health (HIMS) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Hims & Hers Health (HIMS) at $21.46 a share. The stock last closed at $18.56, which puts the model's fair value 15.6% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Hims & Hers Health, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $26.81 to $21.46 (-20.0%). The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $18.56 is 15.6% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 22 Feb 2027. Options prices imply a move of about 21% either way over the next month. On the model's Scorecard Leaders list since 10 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give HIMS?
The calibrated range for HIMS over 63 trading days is $14.57 to $23.94. It sits around the last close, and its width comes from the volatility that HIMS's own options imply (73% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $15.62 to $28.82. In 58% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Hims & Hers Health, Inc. (HIMS) operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care.
Faircurve's model put the fair value at $21.46 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $26.81, so the fair value moved -20.0%. In the model's own words, the stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $15.39 to $25.61, built around the price from the volatility the stock's own options imply. Calibrated weekly against realised prices, using 8,038 past valuations, ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade reflects input completeness, comparable count and agreement, and range width. It does not say whether the fair value is right.
Hims & Hers Health scores 57 out of 100 on the model's overall quality measure, a composite of six quality factors scored against comparable companies. Earnings quality scores 100 and growth quality 97, where trailing revenue growth of 59.0% compares with a peer median of 20.1%. Profitability scores 5, with ROIC of -11.2% against a peer median of 11.9%. The model compares the company with Option Care Health, Inc. (OPCH), Concentra Group Holdings Parent, Inc. (CON), Chemed Corporation (CHE), Addus HomeCare Corporation (ADUS) and Universal Health Services, Inc. (UHS).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does HIMS report earnings, and how has the stock reacted?
Hims & Hers Health's next earnings report is scheduled for 22 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 9.8% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. HIMS's 30 day implied volatility works out to about 21.2% over one month.
On 10 Nov 2026 HIMS moved 16.6% in one session, against the 6.2% a day that options had priced: 2.7 times the implied size, around an earnings report.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across HIMS's last 8 reports, ignoring direction, was 8.6%.
What the options market has priced for a month's move in HIMS
How does HIMS score on business quality?
Hims & Hers Health's overall quality score is 57 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 5 | -11.2%ROIC | 11.9% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 97 | 59.0%Revenue growth, trailing | 20.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 69 | 2.3%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 75 | -8.35xNet debt / EBITDA | -4.51x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 14 | 14.2 ptsEBITDA margin downside volatility, 5y | 6.0 pts |
How does HIMS compare with similar companies?
The companies in medical care facilities closest to Hims & Hers Health in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| OPCH Option Care Health, Inc. | $31.71 | $32.92 | +3.8% | Fairly valued |
| CON Concentra Group Holdings Parent, Inc. | $43.44 | $43.92 | +1.1% | Fairly valued |
| ACHC Acadia Healthcare Company, Inc. | $38.70 | $44.44 | +14.8% | Low evidence grade |
| NHC National HealthCare Corporation | $207.19 | $249.00 | +20.2% | Low evidence grade |
| CHE Chemed Corporation | $549.45 | $568.98 | +3.6% | Fairly valued |
| MD Pediatrix Medical Group, Inc. | $31.89 | $35.38 | +10.9% | Low evidence grade |
| ADUS Addus HomeCare Corporation | $124.61 | $133.49 | +7.1% | Fairly valued |
| UHS Universal Health Services, Inc. | $197.80 | $310.03 | +56.7% | Undervalued |
What the comparable companies' multiples alone would give for HIMS, the peer-implied price, is $30.76 a share on this run. The fair value weighs that against the company's own multiple.
All medical care facilities stocks ranked by gap to fair value
Hims & Hers Health at a glance
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care.
- Market value
- $4.4B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Revenue expected, next twelve months
- $3.8B
- Consensus revenue growth, next fiscal year
- +34.5%
- Analysts with estimates
- 8
- Beta to the US market
- 2.52
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. HIMS was among them.
How the fair value is worked out: the model prices Hims & Hers Health on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for HIMS was $26.81. As of 14 Nov 2026 it is $21.46, a change of -20.0%. The stock's own trading multiple fell with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Hims & Hers Health's valuation
Is Hims & Hers Health stock undervalued or overvalued?
On Faircurve's model, HIMS reads as Undervalued as of 14 Nov 2026. The model's fair value is $21.46 a share against a last close of $18.56, a gap of +15.6%.
What is HIMS's fair value?
$21.46 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $15.62 to $28.82.
What price range does the model give HIMS?
$14.57 to $23.94 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Hims & Hers Health report earnings next?
The next report is scheduled for 22 Feb 2027. Companies can move their dates.
How much has HIMS moved on past earnings reports?
Across its last 8 reports the median two session move was 8.6%, ignoring direction. The largest was -26.4% around the report of 9 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for HIMS is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on HIMS
The model has an idea open on HIMS under Scorecard Leaders since 10 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on HIMS with their outcomes. A free account is enough.